Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Belantamab Mafodotin + Bortezomib + Dexamethasone Versus 2L+ Relapsed/Refractory Multiple Myeloma Regimens: Lenalidomide-Exposed, Lenalidomide-Refractory, High-Risk Cytogenic, and 2L-Only Subpopulations: A Network Meta-Analysis

Paula Rodríguez-Otero, Joshua Richter, Ajay K. Nooka, Fredrik Schjesvold, Emily Combe, Leanne Cooper, Ollie Schofield, Indeg Sly, Nick Ballew, Jacopo Bitetti, Natalie Boytsov, Simon McNamara, Molly Purser

Blood (2024) 144 (Supplement 1): 7054.

https://doi.org/10.1182/blood-2024-198712

Published: 2024

Journal Articles

Vaccinating Against Mutated RAS in Multiple Myeloma: The Phase I/II TG01/QS-21 Study

Hanne Marie Norseth, Hedda Berg Monsen, Nora Remen, Else Marit Inderberg, Helen Vålerhaugen, Laila Helene Bergly, Anna Lysén, Ingerid Weum Abrahamsen, Fredrik Schjesvold

Blood (2024) 144 (Supplement 1): 7053.

https://doi.org/10.1182/blood-2024-198229

Published: 2024

Journal Articles

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Blood (2024) 144 (Supplement 1): 677.

https://doi.org/10.1182/blood-2024-198403

Published: 2024

Journal Articles

Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma

Annemiek Broijl, Fredrik Schjesvold, Abdel el Yaakoubi, Djamila Issa, Sonja Zweegman, Kon-Siong Jie, Mario Boccadoro, Roman Hajek, Bronno van der Holt, Ruth Wester, Pieter Sonneveld

Blood (2024) 144 (Supplement 1): 676.

https://doi.org/10.1182/blood-2024-209809

Published: 2024

Journal Articles

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Elena Zamagni, Tobias Silzle, Ivan Špička, Sabrin Tahri, Sarah Lonergan, Inger S. Nijhof, Antonietta Pia Falcone, Evangelos Terpos, Jakub Radocha, Roberto Mina, Guldane Cengiz Seval, Meral Beksac, Cesar Rodriguez, Marcelo C. Pasquini, Michel Delforge, Vania Hungria, Donna Reece, Philippe Moreau, Yael C. Cohen, Kihyun Kim, Dominik Dytfeld, Jiří Minařík, Irene Strassl, Jelena Bila, Martin Schreder, Janusz Krawczyk, Fredrik Schjesvold, Caroline Cicin-Sain, Christoph Driessen, Gordon Cook, Lugui Qiu, Gonzalo Martin Garate, Agoston Gyula Szabo, Roman Hájek, Marc S. Raab, Silvia Mangiacavalli, Hermann Einsele, Andrew Spencer, Mario Boccadoro, Helen Vassalou, Lixia Pei, Yingqi Shi, Maria Krevvata, Ryan Gruber, Caline Sakabedoyan, Margaret Cobb, Jagoda Jasielec, Himal Amin, Rachel Kobos, Pieter Sonneveld, Niels W.C.J. van de Donk

Blood (2024) 144 (Supplement 1): 494.

https://doi.org/10.1182/blood-2024-205608

Published: 2024

Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Blood (2024) 144 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2024-201630

Published: 2024

Journal Articles

First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2024-204614

Published: 2024

Journal Articles

Selinexor with Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe), Nordic Myeloma Study Group 29/21

Ida Bruun Bruun Kristensen, Hanne Marie Norseth, Diana Loigom, Henrik Gregersen, Einar Haukås, Tobias S. S. Slørdahl, Robert Schou Pedersen, Damian L. Szatkowski, Fredrik Schjesvold, Thomas Lund

Blood (2024) 144 (Supplement 1): 1988.

https://doi.org/10.1182/blood-2024-194840

Published: 2024

Journal Articles

Circulating Tumor Cells As a Biomarker to Identify High-Risk Transplant Eligible Myeloma Patients Treated with Bortezomib, Lenalidomide and Dexamethasone with or without Daratumumab during Induction/Consolidation, and Lenalidomide with or without Daratumumab during Maintenance: Results from the Perseus Study

Blood (2024) 144 (Supplement 1): 487.

https://doi.org/10.1182/blood-2024-199550

Published: 2024

Journal Articles

A Phase II Study Measuring MRD Negativity after Bispecific T-Cell Redirectors Talquetamab and Teclistamab Consolidation Used in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC), Nordic Myeloma Study Group

Blood (2024) 144 (Supplement 1): 7016.

https://doi.org/10.1182/blood-2024-203364

Published: 2024

Journal Articles

Krd Consolidation Abrogates Poor Prognosis of FDG PET/CT Positivity after ASCT: Results from a Phase II Study (CONPET)

Jakob Nordberg Nørgaard, Anna Lysén, Galina Tsykunova, Annette Vangsted, Cristina João, Nora Remen, Lene Kongsgaard Nielsen, Caroline Stokke, James P Connelly, Mona-Elisabeth R. Revheim, Fredrik Schjesvold

Blood (2024) 144 (Supplement 1): 4745.

https://doi.org/10.1182/blood-2024-198925

Published: 2024

Journal Articles

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Blood (2024) 144 (Supplement 1): 773.

https://doi.org/10.1182/blood-2024-201057

Published: 2024

Journal Articles

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 3355.

https://doi.org/10.1182/blood-2024-198119

Published: 2024

Journal Articles

Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Frida Bugge Bugge Askeland, Einar Haukås, Tobias S. S. Slørdahl, Anja Klostergaard, Tatjana Alexandersen, Anna Lysén, Pegah Abdollahi, Emil Hermansen, Fredrik Schjesvold

Blood (2024) 144 (Supplement 1): 4730.

https://doi.org/10.1182/blood-2024-193864

Published: 2024

Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Blood (2023) 142 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2023-191911

Published: 2023

Journal Articles

Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Frida Bugge Askeland, Einar Haukås, Tobias S. Slørdahl, Anja Klostergaard, Tatjana Alexandersen, Diana Schjøll, Anna Lysen, Emil Hermansen, Fredrik Schjesvold

Blood (2023) 142 (Supplement 1): 3381.

https://doi.org/10.1182/blood-2023-173126

Published: 2023

Journal Articles

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 4.

https://doi.org/10.1182/blood-2023-177546

Published: 2023

Journal Articles

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2023-177945

Published: 2023

Journal Articles

Will Survival Improve By Treating Multiple Myeloma Patients at MRD Relapse? the Remnant Study

Frida Bugge Askeland, Anne-Marie Rasmussen, Anna Lysen, Einar Haukås, Anette Løken Eilertsen, Magnus Moksnes, Galina Tsykunova, Anders Vik, Birgitte Dahl Eiken, Vidar Stavseth, Jürgen Rolke, Eivind Ottersen Samstad, Valdas Peceliunas, Randi Fykse Hallstensen, Ariane Aasbø Hansen, Anita Smith Nilsen, Tobias S. Slørdahl, Fredrik Schjesvold

Blood (2023) 142 (Supplement 1): 4755.

https://doi.org/10.1182/blood-2023-189022

Published: 2023

Journal Articles

Upfront Autologous Stem Cell Transplantation in Myeloma Patients >65 Years: A Population-Based Study from the Nordic Myeloma Study Group

Kari Lenita Falck Moore, Anna Genell, Ain Kaare, Dorota Knut-Bojanowska, Diana Loigom, Anna Lysen, Jakob Nordberg Nørgaard, Katrin Palk, Maris Pärnat, Valdas Peceliunas, Sæmundur Rögnvaldsson, Fredrik Schjesvold, Alexander Sigurdsson, Agoston Gyula Szabo, Jonathan Thorsen, Sigrun Thorsteinsdottir, Vilmantė Vaitekėnaitė, Annette J. Vangsted, Cecilie Hveding Blimark

Blood (2023) 142 (Supplement 1): 4729.

https://doi.org/10.1182/blood-2023-172546

Published: 2023

NARROW

Belantamab Mafodotin + Bortezomib + Dexamethasone Versus 2L+ Relapsed/Refractory Multiple Myeloma Regimens: Lenalidomide-Exposed, Lenalidomide-Refractory, High-Risk Cytogenic, and 2L-Only Subpopulations: A Network Meta-Analysis

Vaccinating Against Mutated RAS in Multiple Myeloma: The Phase I/II TG01/QS-21 Study

Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial

Results of the Phase II Randomized Trial EMN15/HOVON147: Carfilzomib-Lenalidomide-Dexamethasone Vs Lenalidomide-Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma

Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma

Selinexor with Alternating Bortezomib or Lenalidomide Plus Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients (SABLe), Nordic Myeloma Study Group 29/21

A Phase II Study Measuring MRD Negativity after Bispecific T-Cell Redirectors Talquetamab and Teclistamab Consolidation Used in Sequence As Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients (TALTEC), Nordic Myeloma Study Group

Krd Consolidation Abrogates Poor Prognosis of FDG PET/CT Positivity after ASCT: Results from a Phase II Study (CONPET)

Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study

Randomized Phase 2 Dose Optimization Trial of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma (RRMM)

Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Replacing Steroids in Transplant-Ineligible Multiple Myeloma: The Phase 2 Isatuximab-Bortezomib-Lenalidomide-Dexamethasone Rest Study

Results of the Phase III Randomized Iskia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Will Survival Improve By Treating Multiple Myeloma Patients at MRD Relapse? the Remnant Study

Upfront Autologous Stem Cell Transplantation in Myeloma Patients >65 Years: A Population-Based Study from the Nordic Myeloma Study Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only